Consolidated Standards of Reporting Trials diagram. PB samples from the final consecutive 173 patients with newly diagnosed FL, treated within the clinical study NHL1-2003 conducted by the German StiL study group, were analyzed for Bcl-2/IgH rearrangements. A total of 107 patients (62%) had a detectable Bcl-2/IgH rearrangement [(q32;q21)(IgH/bcl2)] within the major breakpoint region (MBR) and were selected for serial Bcl-2/IgH quantification.